ÂÜÀòÂÒÂ×

Valmik Bhatt has extensive work experience in the pharmaceutical and bioengineering sectors. Valmik most recently worked at Arranta Bio as a Senior QA Validation Consultant. Prior to this, they were a Validation Engineer at ImmunityBio, Inc. from 2021 to 2022. Before that, Valmik worked as a QA Validation Analyst at Nesher Pharmaceuticals (USA) LLC from 2019 to 2021.

Valmik also has experience in quality assurance, having served as a Quality Assurance Associate at Nutra-Med Packaging Inc. from 2018 to 2019. In this role, they were responsible for ensuring compliance with cGMP, FDA, and DEA regulations.

Earlier in their career, Valmik worked at Modi Antibiotics Private Limited. Valmik held multiple roles at the company, including Regulatory Affairs/Quality Assurance Executive and Pharmacovigilance Intern. In these positions, they contributed to regulatory business practices and supported the continuous improvement ethic of the organization. Valmik also managed various tasks related to pharmacovigilance, including conducting audits, managing administrative functions, and ensuring compliance with regulations and procedures.

Overall, Valmik Bhatt has a diverse background in quality assurance, validation, and regulatory affairs within the pharmaceutical industry.

Valmik Bhatt began their education in 2011 at Gujarat Technological University, where they pursued a Bachelor of Pharmacy (BPharm) degree in Pharmaceutical Sciences. Valmik completed this program in 2015. In 2016, Valmik advanced their education at Long Island University, earning a Master of Science (M.S.) degree in Pharmacy Administration, Pharmacy Policy and Drug Regulatory Affairs. Valmik finished this program in 2018. The following year, in 2019, Valmik attended Campbellsville University to pursue a Master of Business Administration (MBA) degree with a concentration in Business Administration/Project Management. Valmik completed this program in 2020. Aside from their formal education, Valmik also obtained several certifications from the FDA, including GDUFA self-identification SPL submission, Chemistry, manufacturing & controls (CMC) perspective of the IND, FDA eCTD overview and submission, and an overview of the GDUFA Amendments of 2012.